Basic Information
ID: ALA3705568
Type: Binding
Description: Inhibition Assay: Using human p38 MAPK alpha , the p38 MAPK inhibitory activity of Compound (I) was studied by a method partially modified from the method described in Current Medicinal Chemistry (2004, No. 11, pp. 721-730).A solution of each test compound solution in 100% DMSO and a p38alpha /SAPK2a solution (Final Concentration: 1.5 nM) (Invitrogen) were added to a 384-well plate, and then the plate was incubated at room temperature in a dark place for 1 hour. Thereafter, ATP (Final Concentration: 100 uM), which is a phosphate donor, and biotinylated ATF2 (Final Concentration: 30 nM) (upstate), which is a substrate, were added, and the resulting mixture was allowed to react at room temperature in a dark place for 1 hour (the final concentration of DMSO was 0.25%). After the reaction, an anti-phosphorylated ATF2 antibody (Final Concentration: 1 nM) (Cell Signaling), anti-IgG acceptor beads (Final Concentration: 20 ug/mL) (PerkinElmer) and streptavidin donor beads.
Format: BAO_0000357
Organism: Homo sapiens
Target: MAP kinase p38 alpha(ALA260)
Document: ALA3638866
BindingDB Source: 6603
Activity Charts
Bioactivity
Activity Types for Assay ALA3705568
IC50
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 402.47 | 3.40 | 3.40 |
| 452.47 | 4.37 | 4.37 |
| 470.46 | 4.51 | 4.51 |
| 482.50 | 4.38 | 4.38 |
| 499.46 | 3.05 | 3.05 |
| 465.47 | 3.67 | 3.67 |
| 494.51 | 4.14 | 4.14 |
| 466.50 | 4.76 | 4.76 |
| 436.47 | 4.88 | 4.88 |